Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab

J Oncol Pract. 2017 Jul;13(7):462-464. doi: 10.1200/JOP.2016.019224. Epub 2017 May 31.

Authors

Sekwon Jang¹, Suraj Venna¹

Affiliation

¹ Inova Schar Cancer Institute, Fairfax, VA.

PMID: 28562196
DOI: 10.1200/JOP.2016.019224

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Merkel Cell / drug therapy*
Carcinoma, Merkel Cell / virology
Hepacivirus / genetics
Hepatitis C / drug therapy*
Hepatitis C / virology
Humans
Male
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
RNA, Viral / blood
Skin Neoplasms / drug therapy*
Skin Neoplasms / virology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor
RNA, Viral
pembrolizumab